Pliant Therapeutics, INC

Pliant Therapeutics announced its second quarter 2026 financial results, reporting strong enrollment in its Phase 1b FORTIFY trial for PLN-101095 and a reduced net loss.

Pliant Therapeutics, Inc. announced on July 9, 2026, the expansion of its Board of Directors from seven to nine members, appointing Dr. Robert Iannone and Dr. Flavia Borellini.

Pliant Therapeutics stockholders elected three Class III directors, approved executive compensation, and ratified the appointment of Deloitte & Touche LLP.

Pliant Therapeutics reports Q1 2026 financial results, highlighting progress in its PLN-101095 oncology program and a significant reduction in net loss.

Pliant Therapeutics is repricing all employee stock options to $1.33 and navigating the simultaneous retirement of three board members.

Pliant Therapeutics, Inc. announced the termination of its 2021 at-the-market equity offering agreement and confirmed a new $50 million program with Leerink Partners LLC.

Pliant Therapeutics filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued net losses and operational adjustments, while advancing its PLN-101095 oncology program.

Pliant Therapeutics reported a net loss of $20.0 million for the first quarter of 2026, a significant decrease from the prior year's loss of $56.2 million, driven by reduced R&D expenses.

Pliant Therapeutics reported significant net losses and a 45% workforce reduction following the discontinuation of its lead IPF drug, bexotegrast, while advancing its oncology and muscular dystrophy programs.

Pliant Therapeutics discontinues development of bexotegrast in Idiopathic Pulmonary Fibrosis (IPF) due to an unfavorable risk-benefit profile, leading to a workforce reduction and strategic reprioritization of its pipeline.

Pliant Therapeutics reports Q1 2025 results, including the discontinuation of the BEACON-IPF trial and a strategic realignment involving a significant workforce reduction.

Pliant Therapeutics' third quarter 2024 report highlights ongoing clinical trial progress and financial updates, with a focus on their lead drug candidate, bexotegrast.

Pliant Therapeutics halts its Phase 2b BEACON-IPF trial due to safety concerns, despite observing early signs of efficacy, and will reassess its development strategy.

Pliant Therapeutics' 2023 annual report details financial results and significant advancements in their clinical programs, particularly for bexotegrast.

Robert Iannone, a Director of Pliant Therapeutics, Inc., received 60,000 shares of common stock on July 9, 2026.

Flavia Borellini, a Director of Pliant Therapeutics, Inc., received 60,000 shares of common stock on July 9, 2026.

Director Gayle A. Crowell was granted 70,000 stock options in Pliant Therapeutics, Inc. as part of a standard equity compensation arrangement.

Director Thomas A. McCourt was granted 70,000 stock options in Pliant Therapeutics, Inc. as part of standard equity compensation.

Director Steve E. Krognes was granted 70,000 stock options in Pliant Therapeutics as part of standard equity compensation.

Pliant Therapeutics director John T. Curnutte was granted 70,000 stock options as part of his compensation package.

Pliant Therapeutics has issued its 2026 proxy statement detailing director elections, executive compensation, and the ratification of its independent auditor.

Pliant Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 5, 2025, with voting open until June 4, 2025.

Pliant Therapeutics sets date for its 2025 Annual Meeting of Stockholders and proposes an amendment to its charter to limit officer liability.

Pliant Therapeutics has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) regarding its upcoming shareholder meeting.

Pliant Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 13, 2024, featuring proposals for director elections, executive compensation approval, and accounting firm ratification.

Tang Capital Management and its affiliates have disclosed a 9.6% beneficial ownership stake in Pliant Therapeutics, Inc., indicating an investment purpose and potential future discussions regarding strategic alternatives.

ADAR1 Capital Management, LLC and Daniel Schneeberger have jointly filed a Schedule 13G, reporting beneficial ownership of 8.9% of Pliant Therapeutics, Inc. common stock as of June 30, 2026.

Citadel and its affiliates, including Kenneth Griffin, have disclosed a 5.0% beneficial ownership stake in Pliant Therapeutics, Inc. through a Schedule 13G filing.

Citadel entities and Kenneth Griffin have jointly disclosed a 4.9% beneficial ownership stake in Pliant Therapeutics, Inc. common stock.

Citadel Advisors and affiliated entities, including Kenneth Griffin, have disclosed a collective 4.9% passive beneficial ownership in Pliant Therapeutics, Inc. common stock.

Morgan Stanley has reported a reduction in its beneficial ownership of Pliant Therapeutics, Inc. common stock to below 5%.

Woodline Partners LP has reported a 7.3% beneficial ownership stake in Pliant Therapeutics, Inc., holding over 4.5 million shares.